C-Rad AB (publ) (LON:0R44)

Market Cap	97.65M +10.1%
Revenue (ttm)	34.56M -0.2%
Net Income	3.88M +94.4%
EPS	0.12 +97.5%
Shares Out	n/a
PE Ratio	25.19
Forward PE	n/a
Dividend	0.01 (0.29%)
Ex-Dividend Date	May 8, 2026

Volume	931
Open	36.30
Previous Close	36.10
Day's Range	36.30 - 36.50
52-Week Range	25.70 - 36.50
Beta	0.73
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 17, 2026

About C-Rad AB

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports pr...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2004
• Employees: 113
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R44

Financial Performance

In 2025, C-Rad AB's revenue was 441.90 million, a decrease of -5.78% compared to the previous year's 469.00 million. Earnings were 10.46 million, a decrease of -81.47%.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 20, 2026

Data Sources Report a data error